The bleeding disorders community is witnessing a proliferation in the number and types of therapies available to treat hemophilia.
These are exciting times in bleeding disorders research, with new treatment options on the horizon. Come learn about the latest results of various phases of clinical trials
The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s Biologics License Application (BLA) for priority review of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B.
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on gene therapy limitations, risks, and unknowns faqs
NBD provides free quality education on issues that matter to the bleeding disorders community. This video is on gene therapy eligibility faqs
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on gene therapy: the basics and faqs
Clinical trials are key to advancing safe and effective treatments for bleeding disorders. They are an important step in the FDA drug-approval process and provide researchers with invaluable data about a drug’s effectiveness and side effects.
We continue to see significant research and innovation in the treatment of Hemophilia. It is becoming more important than ever to stay informed on all the advancements and innovation – what they are, how they work in the body and how safe they are. Understanding all the options including currently approved treatments, the pros and cons and the promise and limitations of each type of therapy will enable community members to have informative conversations with their providers and to ultimately make the best decision on treatment. This presentation is designed to
Recently there has been an explosion of innovative research in the treatment of Hemophilia utilizing gene therapy technology. This workshop will help you develop a basic understanding of the complexities of gene therapy including terminology, how gene therapy works, and identifying the potential, limitations, risks and unknowns associated with gene therapy. We also provide a brief introduction to other novel therapies and an overview of what treatments are currently approved.
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on candid conversations, what do the docs think?
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on the advancements in treatment for hemophilia
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on gene therapy: where do we go from here
NBDF provides free quality education on issues that matter to the bleeding disorders community. This video is on gene therapy: getting up to speed
This introduction to gene therapy explains how genes work, and how gene therapy can be used to create new therapies for hemophilia.
In this review, the authors discuss some of the primary considerations relevant to investigational gene therapies that employ adeno-associated viral
NHF's Wednesday Webinars for April 2021 will feature an array of speakers and topics of interest to both healthcare providers and patients and families with blood disorders alike.
April Webinars
All webinars are from 2:00pm-3:00pm ET.
In Genentech’s ongoing efforts to transparently communicate with the hemophilia community, we are sharing two updates to the Hemlibra label that were requested by the FDA.
These are exciting times in hemophilia research, with many new treatment options on the horizon. Come learn about the latest results of various phases of clinical trials on gene therapy and other new treatment options to see what the future holds for the treatment of hemophilia.
NOT AVAILABLE FOR CREDIT
*ANCC
Moderators:
Penny Kumpf, RN-BC, BSN
Von Willebrand Outreach Nurse, Hemophilia of Georgia
Kelly Tickle, MSN, APN, PPCNP-BC<
Pediatric Nurse Practitioner, Children’s Healthcare of Atlanta
Speakers:
Lydia Johnson, RN, BSN
Hemostasis Clinical Nurse Coordinator
SSM Cardinal Glennon Children’s Medical Center
Saint Louis Univ. Dept of Pediatrics
*ANCC
Moderator:
Kerry Hansen, RN
Nurse Clinician
University of Minnesota Health, Center for Bleeding and Clotting Disorders
Speaker:
Jim Munn, MS, BS, BSN, RN-BC
Program Nurse Coordinator
Hemophilia and Coagulation Disorders Center, University of Michigan
By the end of this session, the participant should be better able to:
*CME/ACPE
Moderator/Speaker:
Steven W. Pipe, MD, Faculty Chair
Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases,
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program,
Director, Special Coagulation Laboratory,
University of Michigan
Ann Arbor, Michigan
Speakers:
*CME/ACPE
Moderator:
Stacy E. Croteau, MD, MMS
Assistant Professor of Pediatrics, Harvard Medical School Director, Hemophilia/VWD Program, Boston Children's Hospital Medical Director, Boston Hemophilia Center
Dana-Farber/Boston Children's Cancer Center & Blood Disorders Center
Boston, MA
Speakers:
*CME/ACPE
Moderator:
Christopher E. Walsh, MD, PhD
Associate Professor of Medicine, Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
Director, Hemophilia Treatment Center, Mount Sinai Hospital
New York, NY
Speakers:
